TB 500 - Generic Peptides

Buy TB 500 by Generic Peptides at XSteroids. TB 500 is a synthetic heptapeptide modelled on thymosin beta-4, the actin-binding protein present in almost every human cell, and Generic Peptides offers it as a lyophilized vial in three fills, 2 mg, 5 mg and 10 mg. Research interest in this fragment centres on its claimed whole-body action: supplier material describes the injection as travelling systemically rather than acting only where it is placed. This page covers what is physically in the vial, how the peptide interacts with actin, what has actually been observed and in which species, the mixing arithmetic for every vial size, research amounts, stacking, storage and legal status.

Two limits belong at the top. TB 500 itself has never been given to humans in a controlled study, and no human half-life has been established. Everything below comes from laboratory work, the parent protein's clinical record or supplier documentation, not from an approved product label.

What TB 500 Is and What You Are Buying

One glass vial of white lyophilized powder is what the order contains, filled at 2 mg, 5 mg or 10 mg and finished with a rubber stopper and crimp cap. Bacteriostatic water, sterile water, syringes and swabs are bought separately rather than supplied in the box. Three fills share a single listing, so the milligram figure is set on the pack option and stays out of the product name.

Chemically the peptide is the N-acetylated sequence Ac-LKKTETQ, a seven-amino-acid chain that reproduces residues 17 to 23 of the thymosin beta-4 protein. The parent protein is 43 amino acids long, so the fragment is about one sixth of its length. Its identifiers are CAS 885340-08-9 and PubChem 62707662. Vendor blurbs sometimes call TB 500 a 17-amino-acid fragment, while the peptide literature treats it as the acetylated heptapeptide; that is the description followed on this page.

How TB 500 Works at the Actin Site

The actin-binding step

Thymosin beta-4 grips G-actin through the LKKTET motif, and TB 500 copies exactly that segment. By occupying the same site the fragment takes part in actin polymerisation, the process that governs how cells change shape, move and migrate. Supplier descriptions build on that single interaction to list actin binding and cell motility, new blood vessel formation, a drop in pro-inflammatory cytokines, stronger collagen synthesis and faster keratinocyte migration.

What the parent protein does outside the cell

The full protein also acts outside the cell in ways that actin binding does not explain, and this moonlighting behaviour is the source of the wider regeneration claims. The distinction matters to a buyer: evidence for those extracellular effects comes from work on the whole protein, not from the acetylated fragment in this vial.

Pharmacokinetics and the systemic claim

No published human pharmacokinetics exist for TB 500, so peak levels, distribution and clearance are unknown. What survives is a route-related claim: the peptide is injected subcutaneously and is described as acting through the body rather than only at the injection site, which is the practical difference between it and BPC-157 in the same repair category.

What to Expect from TB 500 in Research

The honest summary is that everything mechanistic about this fragment was observed in vitro or in animals. Cell studies show the expected actin interaction, while the angiogenesis, cytokine and collagen observations come from animal work. There is no controlled human injection study to quote and no human marker that has been measured after dosing.

The parent protein holds one narrow slice of human data that is often borrowed unfairly: a thymosin beta-4 eye-drop programme in neurotrophic keratopathy reported complete healing in 6 of 10 treated eyes against 1 of 8 on placebo in one Phase III, while a second European Phase III missed its primary endpoint. That was a topical formulation of the whole protein, not the injected fragment.

Supplier material describes a first one to two weeks in which less pain and inflammation are reported, with tissue changes said to appear over three to six weeks. Treat that timeline as a vendor expectation rather than a measurement, because nobody has published the study that would confirm it.

How to Reconstitute and Dose TB 500

Preparing each vial size

The volume of water is the only variable you control. Add 2 ml to the 2 mg vial and the strength is 1 mg/ml, giving 100 mcg at the 10-unit line of a U-100 syringe; use 1 ml and that line holds 200 mcg instead. The 5 mg vial lands at 2.5 mg/ml with 2 ml, which is 250 mcg per 10 units, or 500 mcg per 10 units when 1 ml is used. The 10 mg vial runs 5 mg/ml with 2 ml, so 10 units give 500 mcg, and 3 ml gives 3.33 mg/ml with roughly 333 mcg per 10 units. Swirl the vial; do not shake it.

Amounts quoted in research

Vendor write-ups set out a four-week loading phase at 2.0 to 2.5 mg given twice weekly, which comes to 4 to 5 mg each week, then move to maintenance at 2.0 to 2.5 mg once weekly. A cycle of six to eight weeks is followed by a break of similar length. On that arithmetic the 2 mg vial is spent in most of one loading week, the 5 mg vial covers one loading week or two to three maintenance weeks, and the 10 mg vial lasts about two loading weeks.

Stacking TB 500 With Other Generic Peptides

The usual partner is BPC-157, described as acting where it is injected while TB 500 is described as acting through the whole body. Growth hormone takes part in connective tissue turnover, so Somatropin and HGH Frag 176-191 appear in the same plans, and Tesamorelin is the closest lipolytic neighbour. For immune-side research the natural companions are Thymosin Alpha-1 and Thymalin.

Recovery and PCT Around TB 500

TB 500 is a peptide rather than a hormone, so it leaves testosterone production alone and brings no post-cycle therapy requirement of its own. If it sits inside a larger stack, recovery concerns whatever else is running: a GH-releasing peptide needs its own break, while Epitalon or NAD+ in a longevity protocol follow their own schedules.

TB 500 Side Effects and Legal Status

Reported side effects

No human safety file exists for the fragment. The thymosin beta-4 eye-drop programme reported no serious adverse events during its Phase III work. Any subcutaneous peptide can leave redness or tenderness where it is placed. The reference literature links raised thymosin beta-4 with tumour development, which is the heaviest caution on this page and the reason a current or past cancer diagnosis is treated as an exclusion.

Anti-doping and legal status

Class S2 of the WADA Prohibited List names thymosin beta-4 and its derivatives, TB-500 appearing there as the worked example, and that class applies continuously. No regulator has approved TB 500 as a medicine; it is sold as a research product.

Handling and Storage of TB 500 Vials

The powder should sit between 2 and 8 C, out of the light, with a freezer reserved for storage that runs into months. A made-up solution stays at 2 to 8 C and is used within 28 to 30 days; freezing it is not an option and long spells at room temperature should be avoided. Let the vial warm up before a draw and wipe the stopper.

Why Buy TB 500 Vials from XSteroids?

All three TB 500 fills, 2 mg, 5 mg and 10 mg, are listed at XSteroids in the Generic Peptides category, which means a stack can be assembled in one order. Compare the BPC-157 card when local repair matters more than a systemic claim, and read Somatropin or HGH Frag 176-191 when connective tissue and growth hormone are the subject.